Featured

Agios Pharmaceuticals, Inc. announced that it has submitted a New Drug Application (NDA) for Mitapivat to the U.S. Food and Drug Administration (FDA) for the treatment of adults with pyruvate…

TIF is excited to be participating in the 26th EHA Annual Congress, held this year virtually on 09 – 17 June 2021. Ms Lily Cannon, TIF Operations Manager, attended a…

June 14 marks World Blood Donor Day 2021. World Blood Donor Day (WBDD) is a very special occasion dedicated to raising global awareness about the insurmountable value of voluntary, non-remunerated…

bluebird bio, Inc. today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical holds on the Phase 1/2 HGB-206 and Phase 3 HGB-210 studies of LentiGlobin…

Read. Learn. Empower. The Thalassaemia International Federation´s internationally acclaimed Educational Programme is a fundamental component of TIF´s work and is specifically designed for and addressed to the ever-growing learning needs…

A new reassuring US study, published recently in the journal Transfusion, suggests that the risk of transmission of SARS-CoV2 through blood transfusion is highly unlikely. For the study, the investigators…

The World Health Organization (WHO) announced yesterday that it has approved a COVID-19 vaccine made by Sinovac Biotech (SVA.O) for emergency use listing, paving the way for a second Chinese shot…

In the midst of the raging COVID-19 pandemic, US President Joe Biden openly supported the World Trade Organization’s (WTO) proposal to lift the proprietary limits on COVID-19 vaccines, in service…

The multi-stakeholder Blood and Beyond initiative recently published a policy briefing shedding light on how the COVID-19 pandemic affects blood use, blood transfusion services, and patients in whom transfusions are…